Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
Results from garenoxacin dry-form broth microdilution MIC panels prepared commercially (Sensititre, TREK Diagnostics) were compared to reference frozen-form MICs to ensure the validity of the longer-shelf-life product. A total of 1078 organisms from seven major organism groups were used in this trial. All commercial MIC results were within +/- one log(2) dilution of reference garenoxacin values, and reproducibility trials produced identical MIC results for 90.5 to 92.1% of garenoxacin MIC comparisons. Control quinolones (ciprofloxacin and gatifloxacin) also performed at a similarly high level of accuracy.
Gordon
Kelley A
KA
The JONES Group/JMI Laboratories, North Liberty, Iowa 52317, USA. kelly.gordon@jmilabs.com
Rhomberg
Paul R
PR
Jones
Ronald N
RN
D000890:Anti-Infective Agents / Q000494:pharmacology*; D003470:Culture Media; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D006094:Gram-Positive Bacteria / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D007211:Indoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results
D000890:Anti-Infective Agents; D003470:Culture Media; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; D011933:Reagent Kits, Diagnostic; C419689:garenoxacin